» Articles » PMID: 33804473

FAM72, Glioblastoma Multiforme (GBM) and Beyond

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Apr 3
PMID 33804473
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Neural stem cells (NSCs) offer great potential for regenerative medicine due to their excellent ability to differentiate into various specialized cell types of the brain. In the central nervous system (CNS), NSC renewal and differentiation are under strict control by the regulation of the pivotal SLIT-ROBO Rho GTPase activating protein 2 (SRGAP2)-Family with sequence similarity 72 (FAM72) master gene (i.e., |-SRGAP2-FAM72-|) via a divergent gene transcription activation mechanism. If the gene transcription control unit (i.e., the intergenic region of the two sub-gene units, SRGAP2 and FAM72) gets out of control, NSCs may transform into cancer stem cells and generate brain tumor cells responsible for brain cancer such as glioblastoma multiforme (GBM). Here, we discuss the surveillance of this |-SRGAP2-FAM72-| master gene and its role in GBM, and also in light of FAM72 for diagnosing various types of cancers outside of the CNS.

Citing Articles

FAM72 family proteins as poor prognostic markers in clear cell renal carcinoma.

Gou H, Chen P, Wu W Biochem Biophys Rep. 2023; 35:101506.

PMID: 37457361 PMC: 10344709. DOI: 10.1016/j.bbrep.2023.101506.


The Role of Hypoxia and Cancer Stem Cells in Development of Glioblastoma.

Shi T, Zhu J, Zhang X, Mao X Cancers (Basel). 2023; 15(9).

PMID: 37174078 PMC: 10177528. DOI: 10.3390/cancers15092613.


Integrated systemic analysis of FAM72A to identify its clinical relevance, biological function, and relationship to drug sensitivity in hepatocellular carcinoma.

Zhou Q, Chen L, Yang L, Zhou H, Chen Y, Guo Y Front Oncol. 2022; 12:1046473.

PMID: 36483027 PMC: 9723133. DOI: 10.3389/fonc.2022.1046473.


Identification of a Chemotherapeutic Lead Molecule for the Potential Disruption of the FAM72A-UNG2 Interaction to Interfere with Genome Stability, Centromere Formation, and Genome Editing.

Renganathan S, Pramanik S, Ekambaram R, Kutzner A, Kim P, Heese K Cancers (Basel). 2021; 13(22).

PMID: 34831023 PMC: 8616359. DOI: 10.3390/cancers13225870.


Novel Treatment Strategies for Glioblastoma-A Summary.

Stylli S Cancers (Basel). 2021; 13(22).

PMID: 34831020 PMC: 8616394. DOI: 10.3390/cancers13225868.


References
1.
Wang X, Sun Q . TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2016; 8(1):624-643. PMC: 5352183. DOI: 10.18632/oncotarget.13483. View

2.
Ghanem N, Andrusiak M, Svoboda D, Al Lafi S, Julian L, McClellan K . The Rb/E2F pathway modulates neurogenesis through direct regulation of the Dlx1/Dlx2 bigene cluster. J Neurosci. 2012; 32(24):8219-30. PMC: 6703648. DOI: 10.1523/JNEUROSCI.1344-12.2012. View

3.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J . AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015; 7(314):314ra185. PMC: 5279222. DOI: 10.1126/scitranslmed.aac5272. View

4.
Nehar S, Mishra M, Heese K . Identification and characterisation of the novel amyloid-beta peptide-induced protein p17. FEBS Lett. 2009; 583(19):3247-53. DOI: 10.1016/j.febslet.2009.09.018. View

5.
Vicente C, Conchillo A, Garcia-Sanchez M, Odero M . The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol. 2011; 82(1):1-17. DOI: 10.1016/j.critrevonc.2011.04.007. View